CEDAR 43453 (18810-8064

February 4, 200

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE In re application of:

Keith L. Black and Nagendra S. Ningaraj

Serial No. 09/491,500

January 26, 2000

METHOD FOR USING POTASSIUM CHANNEL

AGONISTS FOR DELIVERING A MEDICANT TO AN ABNORMAL BRAIN REGION AND/OR A MALIGNANT

TUMOR

TECH CENTER 16於2900er:

RECEIV起

FEB 1 4 2003

Filed:

Baker, Anne Marie

1632

Confirmation No.

8610

TRANSMITTAL OF PREVIOUSLY FILED SEQUENCE LISTING

Assistant Commissioner for Patents U.S. Patent and Trademark Office Box Sequence P. O. Box 2327 Arlington, VA 22202

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS

Dear Sir or Madam:

Pursuant to a telephonic request made by the Examiner on February 3, 2003, submitted herewith are copies of the following items that Applicant mailed to the United States Patent and Trademark Office on October 30, 2002, in response to an Office Action (under Ex Parte Quayle) issued September 12, 2002.

- 1. Declaration Under 37 C.F.R. §1.821 (f) a
- 2. Paper copy of Sequence
- 3. Computer Readable Diskel

LA1 483735v1

4. Copy of Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

The above-referenced items were enclosed in the same envelope as Applicant's response to the Office Action and mailed to the "20231" zip code address. Based on the Examiner's telephonic remarks on February 3, 2003, it is believed that the diskette was destroyed during the USPTO's mail processing procedures.

Applicant believes that there is no fee incurred in this submission, however, Examiner is authorized to charge any fee deficiency or credit any overpayment deemed necessary to Deposit Account 50-1597.

Respectfully submitted,

Nisan A. Steinberg, Ph.D.

Registration No. 40,345

SIDLEY AUSTIN BROWN & WOOD LLP 555 West Fifth Street Los Angeles, California 90013-1010

Ofc: 213/ 896-6665 Fax: 213/896-6600

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
X	This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
X	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other: The specification and/or figures must be amended to identify all disclosed sequences by their sequence identifier (i.e., SEQ ID NO), in accordance with 37 CFR 1.821(d). Applicant is reminded that the specification and figures should be reviewed for sequence disclosures and that each sequence disclosures to be identified by its sequence identifier (i.e., SEQ ID NO).
Applicant Must Provide:	
X	An initial computer readable form (CRF) copy of the "Sequence Listing".
X	An initial paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
	questions regarding compliance to these requirements, please contact:
	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212
	entin Software Program Support

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

Technical Assistance......703-287-0200
To Purchase Patentin Software......703-306-2600

A reply to a notice to comply with the sequence rules should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office.

Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

1. Electronically submitted through EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm, EFS Submission User Manual - ePAVE)

2. Mailed to: U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, VA 22202

3. Mailed by Federal Express, United Parcel Service or other delivery service to:
U. S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Box Sequence
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202

4. Hand Carried directly to the Customer Window at: 2011 South Clark Place Crystal Plaza Two, Lobby, Room 1803, Box Sequence, Arlington, Virginia 22202